Anixa Biosciences (ANIX) 10-Q 9 Jun 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Apr. 30, 2020	Jun. 09, 2020
Document Information Line Items
Entity Registrant Name	Anixa Biosciences Inc
Document Type	10-Q
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding		22,975,950
Amendment Flag	false
Entity Central Index Key	0000715446
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Apr. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Apr. 30, 2020	Oct. 31, 2019
Current assets:
Cash and cash equivalents	$ 2,888,197	$ 3,491,625
Short-term investments in certificates of deposit	2,620,000	2,350,000
Receivables	32,338	66,527
Prepaid expenses and other current assets	116,252	184,972
Total current assets	5,656,787	6,093,124
Property and equipment, net of accumulated depreciation of $124,433 and $95,015, respectively	186,942	200,569
Operating lease right-of-use asset	81,166
Total assets	5,924,895	6,293,693
Current liabilities:
Accounts payable	170,778	585,817
Accrued expenses	850,155	895,498
Operating lease liability	55,748
Total current liabilities	1,076,681	1,481,315
Operating lease liability, non-current	25,964
Total liabilities	1,102,645	1,481,315
Commitments and contingencies (Note 9)
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding, Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding
Common stock, par value $.01 per share; 48,000,000 shares authorized; 21,479,335 and 20,331,754 shares issued and outstanding, respectively	214,793	203,317
Additional paid-in capital	192,122,260	186,849,299
Accumulated deficit	(187,049,899)	(181,817,263)
Total shareholders’ equity	5,287,154	5,235,353
Noncontrolling interest (Note 1)	(464,904)	(422,975)
Total equity	4,822,250	4,812,378
Total liabilities and equity	5,924,895	6,293,693
Series A Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding, Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding
Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding, Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Apr. 30, 2020	Oct. 31, 2019
Property and equipment, accumulated depreciation (in Dollars)	$ 124,433	$ 95,015
Common stock par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	48,000,000	48,000,000
Common stock, shares issued	21,479,335	20,331,754
Common stock, shares outstanding	21,479,335	20,331,754
Series A Preferred Stock [Member]
Preferred stock par value (in Dollars per share)	$ 100	$ 100
Preferred stock, shares authorized	140	140
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred Stock [Member]
Preferred stock par value (in Dollars per share)	$ 100	$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Income Statement [Abstract]
Revenue		$ 250,000		$ 250,000
Operating costs and expenses:
Inventor royalties, contingent legal fees, litigation and licensing expenses related to patent assertion		166,250		166,250
Amortization of patents		125,625		376,875
Research and development expenses (including non-cash share-based compensation expenses of $458,132, $655,066, $855,655 and $2,228,845 respectively)	1,228,790	1,269,393	2,719,378	3,516,665
General and administrative expenses (including non-cash share-based compensation expenses of $651,954, $666,384, $1,275,765 and $1,842,769 respectively)	1,441,347	1,281,966	2,580,628	3,348,422
Impairment in carrying amount of patent asset (Note 1)				418,750
Total operating costs and expenses	2,670,137	2,843,234	5,300,006	7,826,962
Loss from operations	(2,670,137)	(2,593,234)	(5,300,006)	(7,576,962)
Interest income	12,147	18,300	25,441	35,419
Loss before income taxes	(2,657,990)	(2,574,934)	(5,274,565)	(7,541,543)
Provision for income taxes
Net loss	(2,657,990)	(2,574,934)	(5,274,565)	(7,541,543)
Less: Net loss attributable to noncontrolling interest	(17,897)	(37,242)	(41,929)	(122,010)
Net loss attributable to common shareholders	$ (2,640,093)	$ (2,537,692)	$ (5,232,636)	$ (7,419,533)
Net loss per common share attributable to common shareholders:
Basic and diluted (in Dollars per share)	$ (0.12)	$ (0.13)	$ (0.25)	$ (0.38)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	21,155,505	19,645,140	20,927,212	19,403,933

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parentheticals) - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Research and Development Expense [Member]
Non-cash share-based compensation expenses	$ 458,132	$ 655,066	$ 855,655	$ 2,228,845
Selling, General and Administrative Expenses [Member]
Non-cash share-based compensation expenses	$ 651,954	$ 666,384	$ 1,275,765	$ 1,842,769

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (UNAUDITED) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Oct. 31, 2018	$ 189,086	$ 175,415,931	$ (170,170,209)	$ 5,434,808	$ (251,377)	$ 5,183,431
Balance (in Shares) at Oct. 31, 2018	18,908,632
Stock option compensation to employees and directors		2,024,664		2,024,664		2,024,664
Stock options and warrants issued to consultants		92,509		92,509		92,509
Common stock issued upon exercise of stock options	$ 300	79,500		79,800		79,800
Common stock issued upon exercise of stock options (in Shares)	30,000
Restricted stock award compensation to employee pursuant to stock incentive plan		1,954,441		1,954,441		1,954,441
Common stock issued pursuant to employee stock purchase plan	$ 54	18,506		18,560		18,560
Common stock issued pursuant to employee stock purchase plan (in Shares)	5,411
Common stock issued in at-the-market offering, net of offering expenses of $158,296/$57,324/$152,911/$85,750	$ 10,610	4,347,193		4,357,803		4,357,803
Common stock issued in at-the-market offering, net of offering expenses of $158,296/$57,324/$152,911/$85,750 (in Shares)	1,061,032
Net loss			(7,419,533)	(7,419,533)	(122,010)	(7,541,543)
Balance at Apr. 30, 2019	$ 200,050	183,932,744	(177,589,742)	6,543,052	(373,387)	6,169,665
Balance (in Shares) at Apr. 30, 2019	20,005,075
Balance at Jan. 31, 2019	$ 194,702	180,336,763	(175,052,050)	5,479,415	(336,145)	5,143,270
Balance (in Shares) at Jan. 31, 2019	19,470,235
Stock option compensation to employees and directors		805,104		805,104		805,104
Stock options and warrants issued to consultants		46,290		46,290		46,290
Common stock issued upon exercise of stock options	$ 200	56,900		57,100		57,100
Common stock issued upon exercise of stock options (in Shares)	20,000
Restricted stock award compensation to employee pursuant to stock incentive plan		470,056		470,056		470,056
Common stock issued pursuant to employee stock purchase plan	$ 54	18,506		18,560		18,560
Common stock issued pursuant to employee stock purchase plan (in Shares)	5,411
Common stock issued in at-the-market offering, net of offering expenses of $158,296/$57,324/$152,911/$85,750	$ 5,094	2,199,125		2,204,219		2,204,219
Common stock issued in at-the-market offering, net of offering expenses of $158,296/$57,324/$152,911/$85,750 (in Shares)	509,429
Net loss			(2,537,692)	(2,537,692)	(37,242)	(2,574,934)
Balance at Apr. 30, 2019	$ 200,050	183,932,744	(177,589,742)	6,543,052	(373,387)	6,169,665
Balance (in Shares) at Apr. 30, 2019	20,005,075
Balance at Oct. 31, 2019	$ 203,317	186,849,299	(181,817,263)	5,235,353	(422,975)	4,812,378
Balance (in Shares) at Oct. 31, 2019	20,331,754
Stock option compensation to employees and directors		2,019,211		2,019,211		2,019,211
Stock options issued to consultants		112,209		112,209		112,209
Common stock issued upon exercise of stock options	$ 439	103,291		103,730		103,730
Common stock issued upon exercise of stock options (in Shares)	43,900
Common stock issued pursuant to employee stock purchase plan	$ 96	15,356		15,452		15,452
Common stock issued pursuant to employee stock purchase plan (in Shares)	9,618
Common stock issued in at-the-market offering, net of offering expenses of $158,296/$57,324/$152,911/$85,750	$ 10,941	3,022,894		3,033,835		3,033,835
Common stock issued in at-the-market offering, net of offering expenses of $158,296/$57,324/$152,911/$85,750 (in Shares)	1,094,063
Net loss			(5,232,636)	(5,232,636)	(41,929)	(5,274,565)
Balance at Apr. 30, 2020	$ 214,793	192,122,260	(187,049,899)	5,287,154	(464,904)	4,822,250
Balance (in Shares) at Apr. 30, 2020	21,479,335
Balance at Jan. 31, 2020	$ 208,413	189,646,000	(184,409,806)	5,444,607	(447,007)	4,997,600
Balance (in Shares) at Jan. 31, 2020	20,841,309
Stock option compensation to employees and directors		1,055,331		1,055,331		1,055,331
Stock options and warrants issued to consultants		54,755		54,755		54,755
Common stock issued upon exercise of stock options	$ 250	75,000		75,250		75,250
Common stock issued upon exercise of stock options (in Shares)	25,000
Common stock issued pursuant to employee stock purchase plan	$ 96	15,356		15,452		15,452
Common stock issued pursuant to employee stock purchase plan (in Shares)	9,618
Common stock issued in at-the-market offering, net of offering expenses of $158,296/$57,324/$152,911/$85,750	$ 6,034	1,275,818		1,281,852		1,281,852
Common stock issued in at-the-market offering, net of offering expenses of $158,296/$57,324/$152,911/$85,750 (in Shares)	603,408
Net loss			(2,640,093)	(2,640,093)	(17,897)	(2,657,990)
Balance at Apr. 30, 2020	$ 214,793	$ 192,122,260	$ (187,049,899)	$ 5,287,154	$ (464,904)	$ 4,822,250
Balance (in Shares) at Apr. 30, 2020	21,479,335

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (UNAUDITED) (Parentheticals) - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Statement of Stockholders' Equity [Abstract]
Common Stock, offering expenses	$ 57,324	$ 85,750	$ 158,296	$ 152,911

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Cash flows from operating activities:
Net loss	$ (5,274,565)	$ (7,541,543)
Stock option compensation to employees and directors	2,019,211	2,024,664
Stock options and warrants issued to consultants	112,209	92,509
Restricted stock award compensation to employee pursuant to stock incentive plan		1,954,441
Depreciation of property and equipment	29,418	18,108
Amortization of operating lease right-of-use asset, net of lease payments	546
Amortization of patents		376,875
Impairment in carrying amount of patent assets		418,750
Change in operating assets and liabilities:
Receivables	34,189	(489,963)
Prepaid expenses and other current assets	68,720	51,219
Accounts payable	(415,039)	135,908
Accrued expenses	(45,343)	194,742
Net cash used in operating activities	(3,470,654)	(2,764,290)
Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit	(2,620,000)	(1,000,000)
Proceeds from maturities of short-term investments in certificates of deposit	2,350,000	250,000
Purchase of property and equipment	(15,791)	(175,457)
Net cash used in investing activities	(285,791)	(925,457)
Cash flows from financing activities:
Net proceeds from sale of common stock in at-the-market offering	3,033,835	4,357,803
Proceeds from sale of common stock pursuant to employee stock purchase plan	15,452	18,560
Proceeds from exercise of stock options	103,730	79,800
Net cash provided by financing activities	3,153,017	4,456,163
Net (decrease) increase in cash and cash equivalents	(603,428)	766,416
Cash and cash equivalents at beginning of period	3,491,625	3,055,890
Cash and cash equivalents at end of period	2,888,197	3,822,306
Supplemental disclosure of non-cash investing and financing activities:
Operating lease right-of-use asset	(106,221)
Operating lease liability	$ 106,299

BUSINESS AND FUNDING

BUSINESS AND FUNDING	6 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Our primary operations involve developing a number of programs addressing cancer and infectious disease. Our therapeutics programs consist of development of a vaccine against triple negative breast cancer (“TNBC”), development of chimeric endocrine receptor T-cell technology, a novel form of CAR-T technology, initially focused on treating ovarian cancer, and discovery and ultimately development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein function. Our cancer diagnostics program consists of development of the artificial intelligence (AI) driven Cchek™ liquid biopsy platform for early cancer detection. We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) related to certain breast cancer vaccine technology developed at Cleveland Clinic. We are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused specifically on TNBC, the most lethal form of the disease. A specific protein, alpha-lactalbumin, has been identified that is only present during lactation in healthy women, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. We are working with researchers at Cleveland Clinic to advance this vaccine toward human clinical testing, and we are in the process of manufacturing the vaccine and upon completion we will be prepared to file an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”). While we anticipate filing the IND during the third calendar quarter of 2020, we may experience delays in the vaccine manufacturing and characterization process due to the global coronavirus pandemic. We do not currently anticipate any potential delays to significantly alter our expected timeline. The IND application, after review and approval by the FDA, will enable us to begin testing our vaccine in human subjects. Our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”) relating to Wistar’s CAR-T technology. We have initially focused on the development of a treatment for ovarian cancer, but we may also pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent (5%) of the common stock of Certainty. Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), is advancing toward human clinical testing its CAR-T technology for treating ovarian cancer. Clinical grade materials are currently being manufactured and upon completion will undergo extensive testing. Once the materials have been successfully tested, we will be prepared to submit an IND application with the FDA. While we anticipate filing the IND by the end of 2020, we may experience delays in completing the manufacturing and testing of clinical materials due to the global coronavirus pandemic. We do not currently anticipate any potential delays to significantly alter our expected timeline. The IND application, after review and approval by the FDA, will enable us to begin testing our therapy in ovarian cancer patients. In April 2020, in collaboration with OntoChem GmbH (“OntoChem”), we have commenced a project to discover and ultimately develop anti-viral drug candidates for COVID-19. Through this collaboration, we are utilizing advanced computational methods, machine learning, and molecular modeling techniques to perform in silico While the screening process is ongoing and we anticipate discovering several drug candidates, we have identified a lead molecule as well as three similar analog compounds. Our in silico in vitro Our subsidiary, Anixa Diagnostics Corporation (“Anixa Diagnostics”), is developing Cchek™, an AI driven platform of non-invasive blood tests for the early detection of cancer which is based on the body’s immune response to the presence of a malignancy. We have demonstrated the efficacy of Cchek™ with 20 different types of cancer: breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar, prostate, bladder, cervical, head and neck, gastric and testicular cancers. Breast, lung, colon and prostate cancers represent the four largest categories of cancer worldwide. Based on a number of factors, including key scientific, clinical, and commercial considerations, for the past year the primary commercial focus for Cchek™ has been on developing a prostate cancer confirmatory test. In February 2019 we formed a strategic alliance with ResearchDx, a CLIA certified, CAP Accredited laboratory, to prepare the Cchek™ Prostate Cancer Confirmation (“Cchek™ PCC”) test for launch as a laboratory developed test. In December 2019, upon completion of independent analytical validation by ResearchDx, we announced the commercial launch of Cchek™ PCC. We are currently conducting a number of activities to support the marketing of Cchek™ PCC, including the completion of a clinical validation study, development of marketing materials, education of key opinion leaders in urology and development of a reimbursement path for the test. These activities, including the clinical validation study, have been delayed for a number of reasons, including the global coronavirus pandemic. Over the next several quarters, we expect the development of our breast cancer vaccine, Certainty’s CAR-T technology, our COVID-19 therapeutic discovery program and Anixa Diagnostic’s Cchek™ to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management. Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our cancer therapeutics and diagnostics programs. In addition, while we pursue our cancer therapeutics and diagnostics programs, we may also make investments in and form new companies to develop additional emerging technologies. Funding and Management’s Plans Based on currently available information as of June 9, 2020, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. During the six months ended April 30, 2020, we raised an aggregate of approximately $3,034,000, net of expenses, through the sale of 1,094,063 shares of common stock in our at-the-market equity offerings. This included approximately $427,000, net of expenses, through the sale of 112,238 shares of common stock in an at-the market equity offering which expired in November 2019 and approximately $2,607,000, net of expenses, through the sale of 981,825 shares of common stock in an at-the-market equity offering under which we may issue up to $50 million of common stock. Under our current at-the-market equity program which is currently effective and may remain available for us to use in the future, we may sell an additional approximately $47,248,000 of common stock. We may seek to obtain working capital during our fiscal year 2020 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt could result in dilution to our stockholders. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations . Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the six months ended April 30, 2020: Balance, October 31, 2019 $ (422,975) Net loss attributable to noncontrolling interest (41,929) Balance, April 30, 2020 $ (464,904) Revenue Recognition Since fiscal 2016 our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. On November 1, 2018 we adopted Accounting Standards Update 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers using the modified retrospective method. Upon adoption of ASU 2014-09 we are required to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel, licensing and enforcement related research, consulting and other expenses paid to third-parties and the amortization of patent-related investment costs. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations. Research and Development Expenses Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing a platform for non-invasive blood tests for early detection of cancer, developing immuno-therapy drugs against cancer, development of our breast cancer vaccine and development of anti-viral drugs candidates for COVID-19, are expensed in the consolidated financial statements in the period incurred.

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	6 Months Ended
	Apr. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement [Text Block]	2. STOCK BASED COMPENSATION The Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense The compensation cost for service-based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model We recorded stock-based compensation expense related to service-based stock options granted to employees and directors of approximately $2,019,000 and $1,649,000 during the six months ended April 30, 2020 and 2019, respectively For stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company’s common stock exceeding certain price targets, we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). On May 8, 2018, we issued market condition options to purchase 1,500,000 shares of common stock, vesting at target trading prices of $5.00 to $8.00 per share before May 31, 2021, with implied service periods of three to seven months. In October 2018, the first tranche of 500,000 shares of market condition options became exercisable upon achieving an average closing price above $5.00 per share for twenty consecutive trading days. On November 1, 2018 we adopted Accounting Standards Update 2018-07 (“ASU 2018-07”) for stock options granted to consultants. Upon adoption of ASU 2018-07 we estimated the fair value of unvested service-based and performance-based stock options at the date of adoption, using the Black-Scholes pricing model. Subsequent to adoption of ASU 2018-07, future grants to consultants are measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, consistent with our policy for grants to employees and directors. In prior periods, in accordance with US GAAP, we estimated the fair value of service-based and performance-based stock options granted to consultants at each reporting period using the Black-Scholes pricing model. We recognize the fair value of stock options granted to consultants as consulting expense over the requisite or implied service period of the grant. Stock Option Activity During the six months ended April 30, 2020, we granted options to purchase 800,000 shares of common stock to employees and consultants, with exercise prices ranging from $3.84 to $4.04 per share, pursuant to the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”) Stock Option Plans During the six months ended April 30, 2020, we had three stock option plans: the Anixa Biosciences, Inc. 2003 Share Incentive Plan (the "2003 Share Plan"), the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the "2010 Share Plan") and the 2018 Share Plan, which were adopted by our Board of Directors on April 21, 2003, July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. 2003 Plan During the six months ended April 30, 2020, the remaining outstanding options granted under the 2003 Share Plan expired. In accordance with the provisions of the 2003 Share Plan, the plan terminated with respect to the ability to grant future options on April 21, 2013. Information regarding the 2003 Share Plan for the six months ended April 30, 2020 is as follows: Weighted Average Exercise Price Per Share Aggregate Shares Options outstanding at October 31, 2019 400 $ 17.00 Forfeited (400) $ 17.00 Options outstanding and exercisable at April 30, 2020 - $ -0- $ -0- Information regarding the 2003 Share Plan for the six months ended April 30, 2019 is as follows: Weighted Average Exercise Price Per Share Aggregate Shares Options outstanding at October 31, 2018 12,000 $ 2.77 Exercised (4,000) $ 3.63 Options outstanding and exercisable at April 30, 2019 8,000 $ 2.34 $ 19,666 The following table summarizes information about stock options outstanding and exercisable under the 2003 Share Plan as of April 30, 2019: Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Range of Exercise Prices Number Outstanding and Exercisable $ 0.67 - $17.00 8,000 0.45 $ 2.34 2010 Plan The 2010 Share Plan provides for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of April 30, 2020, the 2010 Share Plan had 800,000 shares available for future grants. Information regarding the 2010 Share Plan for the six months ended April 30, 2020 is as follows: Weighted Average Exercise Price Per Share Aggregate Value Shares Options Outstanding at October 31, 2019 1,998,668 $ 2.80 Exercised (43,900) $ 2.36 Forfeited (5,534) $ 2.58 Options Outstanding at April 30, 2020 1,949,234 $ 2.81 $ 291,195 Options Exercisable at April 30, 2020 1,740,484 $ 2.85 $ 213,820 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2020: Options Outstanding Options Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Weighted Average Exercise Price Range of Exercise Prices Number Outstanding Number Exercisable $0.67 - $2.30 561,500 6.03 $1.56 480,250 5.84 $1.66 $2.58 - $3.13 853,200 3.28 $2.79 853,200 3.72 $2.79 $3.46 - $5.75 534,534 7.69 $4.16 407,034 7.54 $4.38 Information regarding the 2010 Share Plan for the six months ended April 30, 2019 is as follows: Weighted Average Exercise Price Per Share Aggregate Value Shares Options outstanding at October 31, 2018 2,131,868 $ 2.11 Exercised (22,000) $ 2.27 Forfeited (87,200) $ 3.34 Options outstanding at April 30, 2019 2,022,668 $ 2.06 $ 4,452,704 Options exercisable at April 30, 2019 1,580,168 $ 1.88 $ 3,732,441 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2019: Options Outstanding Options Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Weighted Average Exercise Price Range of Exercise Prices Number Outstanding Number Exercisable $0.67 938,000 6.19 $0.67 776,750 5.78 $0.67 $ 2.27 -$ 3.01 610,134 4.07 $2.58 610,134 4.07 $2.58 $ 3.46 -$ 7.00 474,534 8.62 $4.13 193,284 7.64 $4.57 2018 Plan The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and Weighted Average Exercise Price Per Share Aggregate Value Shares Options Outstanding at October 31, 2019 3,935,500 $ 3.74 Granted 800,000 $ 3.85 Options Outstanding at April 30, 2020 4,735,000 $ 3.76 $ -0- Options Exercisable at April 30, 2020 2,107,779 $ 3.75 $ -0- The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of April 30, 2020: Options Outstanding Options Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Weighted Average Exercise Price Range of Exercise Prices Number Outstanding Number Exercisable $3.70 3,100,000 8.03 $3.70 1,566,666 8.03 $3.70 $ 3.84 - $4.61 1,635,000 8.92 $3.88 541,113 8.37 $3.75 Information regarding the 2018 Share Plan for the six months ended April 30, 2019 is as follows: Weighted Average Exercise Price Per Share Aggregate Value Shares Options outstanding at October 31, 2018 3,482,000 $ 3.73 Exercised (4,000) $ 3.84 Forfeited (8,000) $ 3.84 Options outstanding at April 30, 2019 3,470,000 $ 3.73 $ 1,525,200 Options exercisable at April 30, 2019 1,156,947 $ 3.72 $ 511,156 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of April 30, 2019: Options Outstanding Options Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Weighted Average Exercise Price Range of Exercise Prices Number Outstanding Number Exercisable $ 3.70 - $4.61 3,470,000 9.03 $3.73 1,156,947 9.02 $ 3.72 Outside of Share Plans In addition to options granted under the 2003 Share Plan, the 2010 Share Plan and the 2018 Share Plan, during the years ended October 31, 2012 and 2013, the Board of Directors approved the grant of stock options to certain employees and directors. Information regarding stock options that were granted outside of Share Plans for the six months ended April 30, 2020 is as follows: Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Shares Options Outstanding at October 31, 2019 1,698,000 $ 2.58 $ -0- Options Outstanding and exercisable at April 30, 2020 1,698,000 $ 2.58 $ -0- The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of April 30, 2020: Weighted Average Remaining Contractual Life (in years) Number Outstanding Exercisable Weighted Average Exercise Price Range of Exercise Prices $2.58 1,698,000 2.25 $ 2.58 Information regarding stock options that were granted outside of Share Plans for the six months ended April 30, 2019 is as follows: Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Shares Options outstanding at October 31, 2018 1,780,000 $ 1.58 Options outstanding and exercisable at April 30, 2019 1,780,000 $ 1.58 $ 4,683,960 The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of April 30, 2019: Weighted Average Remaining Contractual Life (in years) Number Outstanding Exercisable Weighted Average Exercise Price Range of Exercise Prices $0.67 1,046,000 3.30 $ 0.67 $ 2.58-$ 5.56 734,000 2.85 $ 2.88 Stock Awards For stock awards granted to employees, directors and consultants that vest upon grant we recognize expense at the date of grant based on the grant date market price of the underlying common stock. We did not grant any stock awards that vested upon grant during the six months ended April 30, 2020 or 2019. On May 8, 2018, a restricted stock award of 1,500,000 shares of common stock was granted under the 2018 Share Plan to our Chairman, President and Chief Executive Officer. The restricted stock award vests in its entirety upon achievement of a target trading price of $11.00 per share of the Company’s common stock before May 31, 2021. For restricted stock awards vesting a price target of our common stock we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). Employee Stock Purchase Plan The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan which permits eligible employees to purchase shares at not less than 85% of the market value of the Company’s common stock on the offering date or the purchase date of the applicable offering period, whichever is lower. The plan was adopted by our Board of Directors on August 13, 2018 and approved by our shareholders on September 27, 2018. During the six months ended April 30, 2020, employees purchased 9,618 shares with aggregate proceeds of approximately $15,000. Warrants During the six months ended April 30, 2019 we issued a warrant, expiring on November 1, 2023, to purchase 25,000 shares of common stock at $4.04 per share, vesting over 12 months, to a consultant for investor relations services. On November 1, 2019 the warrant was exchanged for a stock option with the same terms as the warrant. During the six-month and three-month periods ended April 30, 2019, we recorded consulting expense of approximately $43,000 and $21,000, respectively, based on the fair value of the warrant recognized on a straight-line basis over the vesting period. No warrants were issued during the six months ended April 30, 2020. As of April 30, 2020, we also had warrants outstanding to purchase 500,000 shares of common stock at $5.03 per share expiring on November 30, 2021.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Apr. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	3. FAIR VALUE MEASUREMENTS US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities. The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of April 30, 2020: Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 2,596,963 $ - $ - $ 2,596,963 Certificates of deposit: Short-term investments - 2,620,000 - 2,620,000 Total financial assets $ 2,596,963 $ 2,620,000 $ - $ 5,216,963 Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 2,706,944 $ - $ - $ 2,706,944 Certificates of deposit: Cash and cash equivalents 500,000 - - 500,000 Short-term investments - 2,350,000 - 2,350,000 Total financial assets $ 3,206,944 $ 2,350,000 $ - $ 5,556,944 The following table presents the hierarchy for our financial liabilities measured at fair value on a recurring basis as of April 30, 2020: Level 1 Level 2 Level 3 Total Operating lease liability $ - $ - $ 81,712 $ 81,712

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Apr. 30, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. ACCRUED EXPENSES Accrued expenses consist of the following as of: April 30, 2020 October 31, 2019 Payroll and related expenses $ 232,456 $ 72,850 Accrued royalty and contingent legal fees 449,691 449,691 Accrued collaborative research and license expenses 158,904 371,710 Accrued other 9,104 1,247 $ 850,155 $ 895,498

NET LOSS PER SHARE OF COMMON ST

NET LOSS PER SHARE OF COMMON STOCK	6 Months Ended
	Apr. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	5. NET LOSS PER SHARE OF COMMON STOCK Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the six and three months ended April 30, 2020 and 2019, were stock options to purchase 8,382,234 and 7,280,668 shares, respectively, and warrants to purchase 500,000 and 854,400 shares, respectively.

EFFECT OF RECENTLY ADOPTED AND

EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	6 Months Ended
	Apr. 30, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]
Accounting Standards Update and Change in Accounting Principle [Text Block]	6. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-02 (“ASU 2016-02”) Accounting Standards Codification Topic 842, Leases (ASC 842), which supersedes Topic 840, Leases, and which requires lessees to recognize most leases on the balance sheet. The new lease standard does not substantially change lessor accounting. For public companies, the standard was effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption was permitted. Lessees and lessors were required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance. In July 2018, FASB issued ASU 2018-11, Leases, which provides an additional transition option for an entity to apply the provisions of ASC 842 by recognizing a cumulative effect adjustment at the effective date of adoption without adjusting the prior comparative periods presented. The requirements of this standard include a significant increase in required disclosures. The Company adopted ASU 2016-02 on November 1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. See Note 8 regarding the accounting and disclosures related to our office lease.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Apr. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	7. INCOME TAXES We file Federal, New York and California state income tax returns. Due to net operating losses, the statute of limitations for Federal and New York State income tax returns remains open to examination by taxing authorities since the fiscal year ended October 31, 1999. We account for interest and penalties related to income tax matters, if any, in general and administrative expenses. There are no unrecognized income tax benefits as of , 2020 and October 31, 2019. We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

LEASES

LEASES	6 Months Ended
	Apr. 30, 2020
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	8. LEASES We lease approximately 2,000 square feet of office space at 3150 Almaden Expressway, San Jose, California (our principal executive offices) from an unrelated party pursuant to an operating lease that expires September 30, 2021. Our base rent is approximately $5,000 per month and the lease provides for annual increases of approximately 3% and an escalation clause for increases in certain operating costs. Under an operating lease that expired on May 31, 2019 we also leased approximately 3,000 square feet of office space at 12100 Wilshire Boulevard, Los Angeles, California (our former executive offices) from an unrelated party. On November 1, 2019, the Company adopted ASC 842, which increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use ("ROU") assets and related operating lease liabilities on the balance sheet. The Company adopted the new guidance using the modified retrospective approach on November 1, 2019. As a result, the condensed consolidated balance sheet as of October 31, 2019 was not restated and is not comparative. The adoption of ASC 842 resulted in the recognition of ROU assets of $106,221, and lease liabilities for operating leases of $106,299 on the Company's condensed consolidated balance sheet as of November 1, 2019. The difference between the ROU assets and the operating lease liability represents the difference between the lease cost and the amount of rent paid in October. The Company elected the package of practical expedients permitted within the standard, which allow an entity to forgo reassessing (i) whether a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has also elected the short-term lease accounting policy under which Anixa would not recognize a lease liability or ROU asset for any lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that Anixa is more than reasonably certain to exercise. For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The remaining 17 month lease term as of April 30, 2020 for the Company’s lease includes the noncancelable period of the lease. The lease does not contain a Company option to extend the lease or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment. Balance sheet information related to the Company’s lease is presented below: Balance Sheet Location April 30, 2020 November 1, 2019 October 31, 2019 Operating Lease: Right-of-use asset Operating lease right- $ 81,166 $ 106,221 $ - Right-of-use liability, Operating lease liability 55,748 51,101 - Right-of-use liability, Operating lease liability, 25,964 55,198 - As of April 30, 2020, the annual minimum lease payments of our operating lease liabilities were as follows: For Years Ending October 31, Operating Leases 2020 (excluding the six months ended April 30, 2020) $ 31,476 2021 59,136 Total future minimum payments, undiscounted 90,612 Less: Imputed interest (8,900) Present value of future minimum lease payments $ 81,712

COMMITMENT AND CONTINGENCES

COMMITMENT AND CONTINGENCES	6 Months Ended
	Apr. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	9. COMMITMENT AND CONTINGENCES Litigation Matters We are not involved in any litigation or other legal proceedings and management is not aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Apr. 30, 2020
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	10. SEGMENT INFORMATION We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) our legacy Patent Licensing activities. The following represents selected financial information for our segments for the six and three months ended April 30, 2020 and 2019 and as of April 30, 2020 and October 31, 2019: For the six Months Ended April 30, 2020 2019 Net loss: CAR-T Therapeutics $ (1,125,363) $ (3,517,219) Cancer Vaccines (365,867) - Anti-Viral Therapeutics (309,504) - Cancer Diagnostics (3,469,673) (3,052,355) Patent Licensing (4,158) (971,969) Total $ (5,274,565) $ (7,541,543) Total operating costs and expenses $ 5,300,006 $ 7,826,962 Less non-cash share-based compensation (2,131,420) (4,071,614) Operating costs and expenses excluding $ 3,168,586 $ 3,755,348 Operating costs and expenses excluding non-cash CAR-T Therapeutics $ 570,163 $ 1,245,681 Cancer Vaccines 165,329 - Anti-Viral Therapeutics 221,018 - Cancer Diagnostics 2,208,813 1,417,967 Patent Licensing 3,263 1,091,700 Total $ 3,168,586 $ 3,755,348 For the Three Months Ended April 30, 2020 2019 Net loss: CAR-T Therapeutics $ (495,030) $ (1,029,934) Cancer Vaccines (170,271) - Anti-Viral Therapeutics (309,504) - Cancer Diagnostics (1,679,027) (1,249,001) Patent Licensing (4,158) (296,999) Total $ (2,657,990) $ (2,574,934) Total operating costs and expenses $ 2,670,137 $ 2,843,234 Less non-cash share-based compensation (1,110,086) (1,321,450) Operating costs and expenses excluding $ 1,560,051 $ 1,521,784 Operating costs and expenses excluding non-cash CAR-T Therapeutics $ 223,822 $ 444,890 Cancer Vaccines 67,059 - Anti-Viral Therapeutics 221,018 - Cancer Diagnostics 1,044,889 658,433 Patent Licensing 3,263 418,461 Total $ 1,560,051 $ 1,521,784 April 30, 2020 October 31, 2019 Total assets: CAR-T Therapeutics $ 1,011,316 $ 2,382,460 Cancer Vaccines 287,831 489,881 Anti-Viral Therapeutics 384,326 - Cancer Diagnostics 4,089,496 2,921,784 Patent Licensing 151,926 499,568 Total $ 5,924,895 $ 6,293,693 Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

IMPACT OF CORONAVIRUS PANDEMIC

IMPACT OF CORONAVIRUS PANDEMIC	6 Months Ended
	Apr. 30, 2020
Unusual or Infrequent Items, or Both [Abstract]
Unusual or Infrequent Items, or Both, Disclosure [Text Block]	11. IMPACT OF CORONAVIRUS PANDEMIC On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had and are expected to continue to have a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and which the Company’s partners operate and conduct their business. We are currently following the recommendations of local health authorities to minimize exposure risk for our team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While we have implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that our continuity plans will be successful. We have already experienced certain disruptions to our business such as temporary closure of our offices and similar disruptions have occurred for our partners. Specifically, the outbreak has caused shutdowns of the laboratories and other service providers that we rely on to develop our CAR-T and breast cancer vaccine programs, and those laboratories and service providers that have been operating or that have begun operating recently have been doing so with more limited capacity due to social distancing requirements. As a result, our progress has been slowed and there is no assurance that we will be able to meet our previously announced timelines regarding the IND filings for our CAR-T therapy for ovarian cancer and for our breast cancer vaccine. Moreover, our plan to sell and/or license our Cchek™ technology to a strategic partner has been impacted by the pandemic even more significantly as we have been unable to complete our clinical validation study for Cchek™ to have a more robust data package for potential partners. The extent to which COVID-19 or any other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on our business, results of operations, financial condition and prospects.

BUSINESS AND FUNDING (Tables)

BUSINESS AND FUNDING (Tables)	6 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Schedule Of Changes In Noncontrolling Interest [Table Text Block]	Balance, October 31, 2019 $ (422,975) Net loss attributable to noncontrolling interest (41,929) Balance, April 30, 2020 $ (464,904)

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	6 Months Ended
	Apr. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Exercise Price Per Share Aggregate Shares Options outstanding at October 31, 2019 400 $ 17.00 Forfeited (400) $ 17.00 Options outstanding and exercisable at April 30, 2020 - $ -0- $ -0- Weighted Average Exercise Price Per Share Aggregate Shares Options outstanding at October 31, 2018 12,000 $ 2.77 Exercised (4,000) $ 3.63 Options outstanding and exercisable at April 30, 2019 8,000 $ 2.34 $ 19,666 Weighted Average Exercise Price Per Share Aggregate Value Shares Options Outstanding at October 31, 2019 1,998,668 $ 2.80 Exercised (43,900) $ 2.36 Forfeited (5,534) $ 2.58 Options Outstanding at April 30, 2020 1,949,234 $ 2.81 $ 291,195 Options Exercisable at April 30, 2020 1,740,484 $ 2.85 $ 213,820 Weighted Average Exercise Price Per Share Aggregate Value Shares Options outstanding at October 31, 2018 2,131,868 $ 2.11 Exercised (22,000) $ 2.27 Forfeited (87,200) $ 3.34 Options outstanding at April 30, 2019 2,022,668 $ 2.06 $ 4,452,704 Options exercisable at April 30, 2019 1,580,168 $ 1.88 $ 3,732,441 Weighted Average Exercise Price Per Share Aggregate Value Shares Options Outstanding at October 31, 2019 3,935,500 $ 3.74 Granted 800,000 $ 3.85 Options Outstanding at April 30, 2020 4,735,000 $ 3.76 $ -0- Options Exercisable at April 30, 2020 2,107,779 $ 3.75 $ -0- Weighted Average Exercise Price Per Share Aggregate Value Shares Options outstanding at October 31, 2018 3,482,000 $ 3.73 Exercised (4,000) $ 3.84 Forfeited (8,000) $ 3.84 Options outstanding at April 30, 2019 3,470,000 $ 3.73 $ 1,525,200 Options exercisable at April 30, 2019 1,156,947 $ 3.72 $ 511,156 Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Shares Options Outstanding at October 31, 2019 1,698,000 $ 2.58 $ -0- Options Outstanding and exercisable at April 30, 2020 1,698,000 $ 2.58 $ -0- Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Shares Options outstanding at October 31, 2018 1,780,000 $ 1.58 Options outstanding and exercisable at April 30, 2019 1,780,000 $ 1.58 $ 4,683,960
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Range of Exercise Prices Number Outstanding and Exercisable $ 0.67 - $17.00 8,000 0.45 $ 2.34 Options Outstanding Options Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Weighted Average Exercise Price Range of Exercise Prices Number Outstanding Number Exercisable $0.67 - $2.30 561,500 6.03 $1.56 480,250 5.84 $1.66 $2.58 - $3.13 853,200 3.28 $2.79 853,200 3.72 $2.79 $3.46 - $5.75 534,534 7.69 $4.16 407,034 7.54 $4.38 Options Outstanding Options Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Weighted Average Exercise Price Range of Exercise Prices Number Outstanding Number Exercisable $0.67 938,000 6.19 $0.67 776,750 5.78 $0.67 $ 2.27 -$ 3.01 610,134 4.07 $2.58 610,134 4.07 $2.58 $ 3.46 -$ 7.00 474,534 8.62 $4.13 193,284 7.64 $4.57 Options Outstanding Options Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Weighted Average Exercise Price Range of Exercise Prices Number Outstanding Number Exercisable $3.70 3,100,000 8.03 $3.70 1,566,666 8.03 $3.70 $ 3.84 - $4.61 1,635,000 8.92 $3.88 541,113 8.37 $3.75 Options Outstanding Options Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Weighted Average Exercise Price Range of Exercise Prices Number Outstanding Number Exercisable $ 3.70 - $4.61 3,470,000 9.03 $3.73 1,156,947 9.02 $ 3.72 Weighted Average Remaining Contractual Life (in years) Number Outstanding Exercisable Weighted Average Exercise Price Range of Exercise Prices $2.58 1,698,000 2.25 $ 2.58 Weighted Average Remaining Contractual Life (in years) Number Outstanding Exercisable Weighted Average Exercise Price Range of Exercise Prices $0.67 1,046,000 3.30 $ 0.67 $ 2.58-$ 5.56 734,000 2.85 $ 2.88

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Apr. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 2,596,963 $ - $ - $ 2,596,963 Certificates of deposit: Short-term investments - 2,620,000 - 2,620,000 Total financial assets $ 2,596,963 $ 2,620,000 $ - $ 5,216,963 Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 2,706,944 $ - $ - $ 2,706,944 Certificates of deposit: Cash and cash equivalents 500,000 - - 500,000 Short-term investments - 2,350,000 - 2,350,000 Total financial assets $ 3,206,944 $ 2,350,000 $ - $ 5,556,944
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total Operating lease liability $ - $ - $ 81,712 $ 81,712

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	6 Months Ended
	Apr. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	April 30, 2020 October 31, 2019 Payroll and related expenses $ 232,456 $ 72,850 Accrued royalty and contingent legal fees 449,691 449,691 Accrued collaborative research and license expenses 158,904 371,710 Accrued other 9,104 1,247 $ 850,155 $ 895,498

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Apr. 30, 2020
Disclosure Text Block [Abstract]
Schedule Of Balance Sheet Information Related To Leases [Table Text Block]	Balance Sheet Location April 30, 2020 November 1, 2019 October 31, 2019 Operating Lease: Right-of-use asset Operating lease right- $ 81,166 $ 106,221 $ - Right-of-use liability, Operating lease liability 55,748 51,101 - Right-of-use liability, Operating lease liability, 25,964 55,198 -
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	For Years Ending October 31, Operating Leases 2020 (excluding the six months ended April 30, 2020) $ 31,476 2021 59,136 Total future minimum payments, undiscounted 90,612 Less: Imputed interest (8,900) Present value of future minimum lease payments $ 81,712

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Apr. 30, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	For the six Months Ended April 30, 2020 2019 Net loss: CAR-T Therapeutics $ (1,125,363) $ (3,517,219) Cancer Vaccines (365,867) - Anti-Viral Therapeutics (309,504) - Cancer Diagnostics (3,469,673) (3,052,355) Patent Licensing (4,158) (971,969) Total $ (5,274,565) $ (7,541,543) Total operating costs and expenses $ 5,300,006 $ 7,826,962 Less non-cash share-based compensation (2,131,420) (4,071,614) Operating costs and expenses excluding $ 3,168,586 $ 3,755,348 Operating costs and expenses excluding non-cash CAR-T Therapeutics $ 570,163 $ 1,245,681 Cancer Vaccines 165,329 - Anti-Viral Therapeutics 221,018 - Cancer Diagnostics 2,208,813 1,417,967 Patent Licensing 3,263 1,091,700 Total $ 3,168,586 $ 3,755,348 For the Three Months Ended April 30, 2020 2019 Net loss: CAR-T Therapeutics $ (495,030) $ (1,029,934) Cancer Vaccines (170,271) - Anti-Viral Therapeutics (309,504) - Cancer Diagnostics (1,679,027) (1,249,001) Patent Licensing (4,158) (296,999) Total $ (2,657,990) $ (2,574,934) Total operating costs and expenses $ 2,670,137 $ 2,843,234 Less non-cash share-based compensation (1,110,086) (1,321,450) Operating costs and expenses excluding $ 1,560,051 $ 1,521,784 Operating costs and expenses excluding non-cash CAR-T Therapeutics $ 223,822 $ 444,890 Cancer Vaccines 67,059 - Anti-Viral Therapeutics 221,018 - Cancer Diagnostics 1,044,889 658,433 Patent Licensing 3,263 418,461 Total $ 1,560,051 $ 1,521,784 April 30, 2020 October 31, 2019 Total assets: CAR-T Therapeutics $ 1,011,316 $ 2,382,460 Cancer Vaccines 287,831 489,881 Anti-Viral Therapeutics 384,326 - Cancer Diagnostics 4,089,496 2,921,784 Patent Licensing 151,926 499,568 Total $ 5,924,895 $ 6,293,693

BUSINESS AND FUNDING (Details)

BUSINESS AND FUNDING (Details) - USD ($)	1 Months Ended	3 Months Ended		5 Months Ended	6 Months Ended
	Nov. 30, 2019	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2020	Apr. 30, 2019
BUSINESS AND FUNDING (Details) [Line Items]
Equity Method Investment, Ownership Percentage		5.00%		5.00%	5.00%
Common stock issued in at-the-market offering, net of offering expenses of $100,972/$67,161		$ 1,281,852	$ 2,204,219		$ 3,033,835	$ 4,357,803
Market Equity Program Available Offering Amount		50,000,000		$ 50,000,000	50,000,000
Market Equity Program Available Additional Offering Amount		$ 47,248,000		47,248,000	47,248,000
Common Stock [Member]
BUSINESS AND FUNDING (Details) [Line Items]
Common stock issued in at-the-market offering, net of offering expenses of $100,972/$67,161	$ 427,000			$ 2,607,000	$ 3,034,000
Stock Issued During Period Shares At The Market Offering (in Shares)	112,238			981,825	1,094,063

BUSINESS AND FUNDING (Details)

BUSINESS AND FUNDING (Details) - Changes in noncontrolling interest - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Changes in noncontrolling interest [Abstract]
Balance			$ (422,975)
Net loss attributable to noncontrolling interest	$ (17,897)	$ (37,242)	(41,929)	$ (122,010)
Balance	$ (464,904)		$ (464,904)

STOCK BASED COMPENSATION (Detai

STOCK BASED COMPENSATION (Details) - Stock Option Compensation Expense - Share-based Payment Arrangement, Option [Member] - USD ($)	May 08, 2018	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019	Oct. 31, 2018
STOCK BASED COMPENSATION (Details) - Stock Option Compensation Expense [Line Items]
Share-based Payment Arrangement, Noncash Expense		$ 1,055,000	$ 805,000	$ 2,019,000	$ 1,649,000
Minimum [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Compensation Expense [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				1 year
Maximum [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Compensation Expense [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years
Chairman President And Chief Executive Officer [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Compensation Expense [Line Items]
Share-based Payment Arrangement, Noncash Expense				$ 0	376,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period (in Shares)	1,500,000
Chairman President And Chief Executive Officer [Member] | Share-based Payment Arrangement, Tranche One [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Compensation Expense [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)						500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)						$ 5
Chairman President And Chief Executive Officer [Member] | Minimum [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Compensation Expense [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 months
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)	$ 5
Chairman President And Chief Executive Officer [Member] | Maximum [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Compensation Expense [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	7 months
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)	$ 8
Consultant [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Compensation Expense [Line Items]
Share-based Payment Arrangement, Noncash Expense		$ 55,000	$ 25,000	$ 112,000	$ 50,000

STOCK BASED COMPENSATION (Det_2

STOCK BASED COMPENSATION (Details) - Stock Option Activity - 2018 Share Plan [Member] - Share-based Payment Arrangement, Option [Member] - USD ($)	6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
STOCK BASED COMPENSATION (Details) - Stock Option Activity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	43,900	30,000
Proceeds from Stock Options Exercised	$ 104,000	$ 80,000
Minimum [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Activity [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$ 3.84
Maximum [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Activity [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$ 4.04

STOCK BASED COMPENSATION (Det_3

STOCK BASED COMPENSATION (Details) - Stock Option Plans	Apr. 30, 2020shares
2010 Share Plan [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	800,000
2018 Share Plan [Member]
STOCK BASED COMPENSATION (Details) - Stock Option Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	2,000,000

STOCK BASED COMPENSATION (Det_4

STOCK BASED COMPENSATION (Details) - Stock Awards - USD ($)	May 08, 2018	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Restricted Stock [Member]
STOCK BASED COMPENSATION (Details) - Stock Awards [Line Items]
Share-based Payment Arrangement, Noncash Expense		$ 470,000		$ 1,954,000
2018 Share Plan [Member]
STOCK BASED COMPENSATION (Details) - Stock Awards [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)			800,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)			$ 3.85
2018 Share Plan [Member] | Restricted Stock [Member] | Chairman President And Chief Executive Officer [Member]
STOCK BASED COMPENSATION (Details) - Stock Awards [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	1,500,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$ 11
Employee Stock Purchase Plan [Member]
STOCK BASED COMPENSATION (Details) - Stock Awards [Line Items]
Share-based Payment Arrangement, Noncash Expense			$ 0

STOCK BASED COMPENSATION (Det_5

STOCK BASED COMPENSATION (Details) - Employee Stock Purchase Plan - Employee Stock Purchase Plan [Member] - USD ($)	6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
STOCK BASED COMPENSATION (Details) - Employee Stock Purchase Plan [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)	9,618	5,411
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 15,000	$ 19,000

STOCK BASED COMPENSATION (Det_6

STOCK BASED COMPENSATION (Details) - Warrants - Common Stock [Member] - Warrant [Member] - USD ($)	3 Months Ended	6 Months Ended
	Apr. 30, 2019	Apr. 30, 2019	Apr. 30, 2020
STOCK BASED COMPENSATION (Details) - Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)			500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 5.03
Consultant [Member]
STOCK BASED COMPENSATION (Details) - Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	25,000	25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 4.04	$ 4.04
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		12 months
Consultation Expense	$ 21,000	$ 43,000

STOCK BASED COMPENSATION (Det_7

STOCK BASED COMPENSATION (Details) - Information regarding the Stock Option Plan - USD ($)	6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
2003 Share Plan [Member]
STOCK BASED COMPENSATION (Details) - Information regarding the Stock Option Plan [Line Items]
Options Outstanding, Shares	400	12,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 17	$ 2.77
Options Exercised, Shares		(4,000)
Options Exercised, Weighted Average Exercise Price Per Share		$ 3.63
Options Forfeited, Shares	(400)
Options Forfeited, Weighted Average Exercise Price Per Share	$ 17
Options Outstanding and exercisable, Shares		8,000
Options Outstanding and exercisable, Weighted Average Exercise Price Per Share	$ 0	$ 2.34
Options Outstanding and exercisable, Aggregate Intrinsic Value	$ 0	$ 19,666
2010 Share Plan [Member]
STOCK BASED COMPENSATION (Details) - Information regarding the Stock Option Plan [Line Items]
Options Outstanding, Shares	1,998,668	2,131,868
Options Outstanding, Weighted Average Exercise Price Per Share	$ 2.80	$ 2.11
Options Exercised, Shares	(43,900)	(22,000)
Options Exercised, Weighted Average Exercise Price Per Share	$ 2.36	$ 2.27
Options Forfeited, Shares	(5,534)	(87,200)
Options Forfeited, Weighted Average Exercise Price Per Share	$ 2.58	$ 3.34
Options Outstanding, Shares	1,949,234	2,022,668
Options Outstanding, Weighted Average Exercise Price Per Share	$ 2.81	$ 2.06
Options Outstanding, Aggregate Intrinsic Value	$ 291,195	$ 4,452,704
Options Exercisable, Shares	1,740,484	1,580,168
Options Exercisable, Weighted Average Exercise Price Per Share	$ 2.85	$ 1.88
Options Exercisable, Aggregate Intrinsic Value	$ 213,820	$ 3,732,441
2018 Share Plan [Member]
STOCK BASED COMPENSATION (Details) - Information regarding the Stock Option Plan [Line Items]
Options Outstanding, Shares	3,935,500	3,482,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 3.74	$ 3.73
Options Granted, Shares	800,000
Options Granted, Weighted Average Exercise Price Per Share	$ 3.85
Options Exercised, Shares		(4,000)
Options Exercised, Weighted Average Exercise Price Per Share		$ 3.84
Options Forfeited, Shares		(8,000)
Options Forfeited, Weighted Average Exercise Price Per Share		$ 3.84
Options Outstanding, Shares	4,735,000	3,470,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 3.76	$ 3.73
Options Outstanding, Aggregate Intrinsic Value	$ 0	$ 1,525,200
Options Exercisable, Shares	2,107,779	1,156,947
Options Exercisable, Weighted Average Exercise Price Per Share	$ 3.75	$ 3.72
Options Exercisable, Aggregate Intrinsic Value	$ 0	$ 511,156
Stock Options Not Granted Under 2003 Share Plan 2010 Share Plan Or 2018 Share Plan [Member]
STOCK BASED COMPENSATION (Details) - Information regarding the Stock Option Plan [Line Items]
Options Outstanding, Shares	1,698,000	1,780,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 2.58	$ 1.58
Options Outstanding, Aggregate Intrinsic Value	$ 0
Options Outstanding and exercisable, Shares	1,698,000	1,780,000
Options Outstanding and exercisable, Weighted Average Exercise Price Per Share	$ 2.58	$ 1.58
Options Outstanding and exercisable, Aggregate Intrinsic Value	$ 0	$ 4,683,960

STOCK BASED COMPENSATION (Det_8

STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under the Stock Option Plan - $ / shares	6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Range Of Exercise Prices $0.67 To $17.00 [Member] | 2003 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstnding and Exercisable, Numbers		8,000
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life		164 days
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share)		$ 2.34
Range Of Exercise Prices $0.67 To $2.30 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number	561,500
Options Outstanding,Weighted Average Remaining Contractual Life	6 years 10 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share)	$ 1.56
Options Exercisable, Number	480,250
Options Exercisable,Weighted Average Remaining Contractual Life	5 years 306 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share)	$ 1.66
Range Of Exercise Prices $2.58 To $3.13 [Member] | 2010 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number	853,200
Options Outstanding,Weighted Average Remaining Contractual Life	3 years 102 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share)	$ 2.79
Options Exercisable, Number	853,200
Options Exercisable,Weighted Average Remaining Contractual Life	3 years 262 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share)	$ 2.79
Range Of Exercise Prices $3.46 To $5.75 [Member] | 2010 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number	534,534
Options Outstanding,Weighted Average Remaining Contractual Life	7 years 251 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share)	$ 4.16
Options Exercisable, Number	407,034
Options Exercisable,Weighted Average Remaining Contractual Life	7 years 197 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share)	$ 4.38
Range Of Exercise Prices $0.67 [Member] | 2010 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number		938,000
Options Outstanding,Weighted Average Remaining Contractual Life		6 years 69 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share)		$ 0.67
Options Exercisable, Number		776,750
Options Exercisable,Weighted Average Remaining Contractual Life		5 years 284 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share)		$ 0.67
Range Of Exercise Prices $0.67 [Member] | Stock Options Not Granted Under 2003 Share Plan 2010 Share Plan Or 2018 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstnding and Exercisable, Numbers		1,046,000
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life		3 years 109 days
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share)		$ 0.67
Range Of Exercise Prices $2.27 To $3.01 [Member] | 2010 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number		610,134
Options Outstanding,Weighted Average Remaining Contractual Life		4 years 25 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share)		$ 2.58
Options Exercisable, Number		610,134
Options Exercisable,Weighted Average Remaining Contractual Life		4 years 25 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share)		$ 2.58
Range Of Exercise Prices $3.46 To $7.00 [Member] | 2010 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number		474,534
Options Outstanding,Weighted Average Remaining Contractual Life		8 years 226 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share)		$ 4.13
Options Exercisable, Number		193,284
Options Exercisable,Weighted Average Remaining Contractual Life		7 years 233 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share)		$ 4.57
Range Of Exercise Prices $3.70 [Member] | 2018 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number	3,100,000
Options Outstanding,Weighted Average Remaining Contractual Life	8 years 10 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share)	$ 3.70
Options Exercisable, Number	1,566,666
Options Exercisable,Weighted Average Remaining Contractual Life	8 years 10 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share)	$ 3.70
Range Of Exercise Prices $3.84 To $4.61 [Member] | 2018 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number	1,635,000
Options Outstanding,Weighted Average Remaining Contractual Life	8 years 335 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share)	$ 3.88
Options Exercisable, Number	541,113
Options Exercisable,Weighted Average Remaining Contractual Life	8 years 135 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share)	$ 3.75
Range Of Exercise Prices $3.70 To $4.61 [Member] | 2018 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number		3,470,000
Options Outstanding,Weighted Average Remaining Contractual Life		9 years 10 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share)		$ 3.73
Options Exercisable, Number		1,156,947
Options Exercisable,Weighted Average Remaining Contractual Life		9 years 7 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share)		$ 3.72
Range Of Exercise Prices $2.58 [Member] | Stock Options Not Granted Under 2003 Share Plan 2010 Share Plan Or 2018 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstnding and Exercisable, Numbers	1,698,000
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life	2 years 3 months
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share)	$ 2.58
Range Of Exercise Prices $2.58 To $5.56 [Member] | Stock Options Not Granted Under 2003 Share Plan 2010 Share Plan Or 2018 Share Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstnding and Exercisable, Numbers		734,000
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life		2 years 310 days
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share)		$ 2.88

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value - USD ($)	Apr. 30, 2020	Oct. 31, 2019
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Total financial assets	$ 5,216,963	$ 5,556,944
Money Market Funds [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Cash and cash equivalents	2,596,963	2,706,944
Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Cash and cash equivalents		500,000
Short-term Investments [Member] | Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Short-term investments	2,620,000	2,350,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Total financial assets	2,596,963	3,206,944
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Cash and cash equivalents	2,596,963	2,706,944
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Cash and cash equivalents		500,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Short-term Investments [Member] | Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Short-term investments
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Total financial assets	2,620,000	2,350,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Cash and cash equivalents
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Cash and cash equivalents
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Short-term Investments [Member] | Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Short-term investments	2,620,000	2,350,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Total financial assets
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Cash and cash equivalents
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Cash and cash equivalents
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Short-term Investments [Member] | Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Short-term investments

FAIR VALUE MEASUREMENTS (Deta_2

FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value	Apr. 30, 2020USD ($)
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value [Line Items]
Operating lease liability	$ 81,712
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value [Line Items]
Operating lease liability
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value [Line Items]
Operating lease liability
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial liabilities measured at fair value [Line Items]
Operating lease liability	$ 81,712

ACCRUED EXPENSES (Details) - Ac

ACCRUED EXPENSES (Details) - Accrued expenses - USD ($)	Apr. 30, 2020	Oct. 31, 2019
Accrued expenses [Abstract]
Payroll and related expenses	$ 232,456	$ 72,850
Accrued royalty and contingent legal fees	449,691	449,691
Accrued collaborative research and license expenses	158,904	371,710
Accrued other	9,104	1,247
Total	$ 850,155	$ 895,498

NET LOSS PER SHARE OF COMMON _2

NET LOSS PER SHARE OF COMMON STOCK (Details) - shares	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Share-based Payment Arrangement, Option [Member]
NET LOSS PER SHARE OF COMMON STOCK (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,382,234	7,280,668	8,382,234	7,280,668
Warrant [Member]
NET LOSS PER SHARE OF COMMON STOCK (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	500,000	854,400	500,000	854,400

LEASES (Details)

LEASES (Details)	3 Months Ended		6 Months Ended
	Apr. 30, 2020USD ($)ft²	Apr. 30, 2019USD ($)	Apr. 30, 2020USD ($)ft²	Apr. 30, 2019USD ($)	Nov. 01, 2019USD ($)	Oct. 31, 2019USD ($)
LEASES (Details) [Line Items]
Monthly Base Rent Expense			$ 5,000
Base Rent Annual Increase Percentage	3.00%		3.00%
Operating Leases, Rent Expense	$ 16,000	$ 12,000	$ 32,000	$ 30,000
Operating Lease, Right-of-Use Asset	81,166		81,166		$ 106,221
Operating Lease, Liability	81,712		81,712
Accounting Standards Update 2016-02 [Member]
LEASES (Details) [Line Items]
Operating Lease, Right-of-Use Asset	106,221		106,221
Operating Lease, Liability	$ 106,299		$ 106,299
Lease Expiring On September 2021 [Member]
LEASES (Details) [Line Items]
Area of Real Estate Property (in Square Feet) | ft²	2,000		2,000
Lease Expired On May 2019 [Member]
LEASES (Details) [Line Items]
Area of Real Estate Property (in Square Feet) | ft²	3,000		3,000

LEASES (Details) - Balance shee

LEASES (Details) - Balance sheet information related to the Company`s lease - USD ($)	Apr. 30, 2020	Nov. 01, 2019	Oct. 31, 2019
Operating Lease:
Right-of-use asset	$ 81,166	$ 106,221
Right-of-use liability, current	55,748	51,101
Right-of-use liability, long-term	$ 25,964	$ 55,198

LEASES (Details) - Annual minim

LEASES (Details) - Annual minimum lease payments	Apr. 30, 2020USD ($)
Annual minimum lease payments [Abstract]
2020 (excluding the six months ended April 30, 2020)	$ 31,476
2021	59,136
Total future minimum payments, undiscounted	90,612
Less: Imputed interest	(8,900)
Present value of future minimum lease payments	$ 81,712

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details)	6 Months Ended
	Apr. 30, 2020
Segment Reporting [Abstract]
Number of Reportable Segments	5

SEGMENT INFORMATION (Details) -

SEGMENT INFORMATION (Details) - Segments Information - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019	Oct. 31, 2019
Net loss:
Net Loss	$ (2,657,990)	$ (2,574,934)	$ (5,274,565)	$ (7,541,543)
Total operating costs and expenses	2,670,137	2,843,234	5,300,006	7,826,962
Less non-cash share-based compensation	(1,110,086)	(1,321,450)	(2,131,420)	(4,071,614)
Operating costs and expenses excluding non-cash share-based compensation	1,560,051	1,521,784	3,168,586	3,755,348
Total assets:
Total Assets	5,924,895		5,924,895		$ 6,293,693
CAR-T Therapeutics [Member] | Operating Segments [Member]
Net loss:
Net Loss	(495,030)	(1,029,934)	(1,125,363)	(3,517,219)
Operating costs and expenses excluding non-cash share-based compensation	223,822	444,890	570,163	1,245,681
Total assets:
Total Assets	1,011,316		1,011,316		2,382,460
Cancer Vaccines [Member] | Operating Segments [Member]
Net loss:
Net Loss	(170,271)		(365,867)
Operating costs and expenses excluding non-cash share-based compensation	67,059		165,329
Total assets:
Total Assets	287,831		287,831		489,881
Anti-Viral Therapeutics [Member] | Operating Segments [Member]
Net loss:
Net Loss	(309,504)		(309,504)
Operating costs and expenses excluding non-cash share-based compensation	221,018		221,018
Total assets:
Total Assets	384,326		384,326
Cancer Diagnostics [Member] | Operating Segments [Member]
Net loss:
Net Loss	(1,679,027)	(1,249,001)	(3,469,673)	(3,052,355)
Operating costs and expenses excluding non-cash share-based compensation	1,044,889	658,433	2,208,813	1,417,967
Total assets:
Total Assets	4,089,496		4,089,496		2,921,784
Patent Licensing [Member] | Operating Segments [Member]
Net loss:
Net Loss	(4,158)	(296,999)	(4,158)	(971,969)
Operating costs and expenses excluding non-cash share-based compensation	3,263	$ 418,461	3,263	$ 1,091,700
Total assets:
Total Assets	$ 151,926		$ 151,926		$ 499,568